FDA approves 4-week dosing for BMS cancer drug

March 6, 2018

The U.S. Food and Drug Administration has approved a four-week dosing schedule for Bristol-Myers Squibb's cancer drug, Opdivo.

 A two-week dosing had already been approved previously and now BMS have announced that the drug is also approved for 30-minute infusions, down from the previous 60-minute infusions.

While the PD-1 inhibitor Opdivo has rivals from Merck and Roche, it is now the only inhibitor to offer four-week dosing.

Read the Reuters report